Zhejiang Cheng Yi Pharmaceutical (603811.SH) has obtained Australia's TGA-GMP certification.

Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that from April 29th, 2024 to May 3rd, 2024, the company underwent a remote inspection by the Therapeutic Goods Administration (TGA) of Australia for cGMP (current Good Manufacturing Practice) for the production of mercaptopurine and thioguanine active pharmaceutical ingredients. Recently, Zhejiang Cheng Yi Pharmaceutical received written notification from TGA indicating that it has passed the certification. This is the third time that Zhejiang Cheng Yi Pharmaceutical has been certified by TGA, with the first certification received in 2010.